![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » International Regulatory Authorities Work to Identify Overlap in Global COVID-19 Trials
International Regulatory Authorities Work to Identify Overlap in Global COVID-19 Trials
June 22, 2020
Members of the International Coalition of Medicines Regulatory Authorities (ICMRA) are working on comparing protocols of ongoing and planned COVID-19 trials with master protocols in different countries to identify potential overlaps, which may hopefully optimize research of the infection by reducing replication across trials.
This work stems from a June 12 meeting of ICMRA members to discuss regulatory approaches to the worldwide coordinated response to the pandemic. The meeting follows a joint statement released in April by ICMRA that recommended prioritization of large, well-designed controlled COVID-19 studies and emphasized a global approach to develop treatments and vaccines for the infection.
Related Directories
Upcoming Events
-
21Oct